How many Apollo Go Robotaxis will Baidu be allowed to operate simultaneously in Hong Kong by end of 2025?
1 vehicle • 25%
2-5 vehicles • 25%
6-10 vehicles • 25%
More than 10 vehicles • 25%
Official announcements from Baidu or the Hong Kong Transport Department
Baidu to Test 10 Apollo Go Robotaxis in Hong Kong, First Trials Outside Mainland China
Dec 1, 2024, 05:28 AM
Baidu Inc., the Chinese technology giant, has secured Hong Kong's first license to test autonomous vehicles in the city, marking a significant step in its efforts to expand driverless technology beyond mainland China. The Hong Kong Transport Department granted Baidu's Apollo unit approval to conduct trials for 10 autonomous vehicles in North Lantau. In the first phase, only one autonomous vehicle is permitted to operate at a time during specified periods for each road test. This development represents Baidu's first permit for autonomous vehicle testing outside the Chinese mainland.
View original story
2-3 cities • 25%
Only Tokyo • 25%
4-5 cities • 25%
More than 5 cities • 25%
5-6 Cities • 25%
3-4 Cities • 25%
1-2 Cities • 25%
7 or more Cities • 25%
501 to 1000 • 25%
Less than 100 • 25%
More than 1000 • 25%
100 to 500 • 25%
Launches with under 50 vehicles • 25%
Launches with over 100 vehicles • 25%
Launches with 50-100 vehicles • 25%
Does not launch • 25%
1,000 to 5,000 rides • 25%
Under 1,000 rides • 25%
5,001 to 10,000 rides • 25%
Over 10,000 rides • 25%
Less than 100 vehicles • 25%
300 or more vehicles • 25%
200-299 vehicles • 25%
100-199 vehicles • 25%
Significant delays due to technical issues • 25%
Successful with no major issues • 25%
Successful with minor issues • 25%
Testing halted due to regulatory issues • 25%
1000 or more • 25%
500 to 999 • 25%
Less than 100 • 25%
100 to 499 • 25%
Full city coverage • 25%
Major districts only • 25%
Limited to initial test areas • 25%
No significant coverage • 25%
Highly successful • 25%
Service discontinued • 25%
Poorly received • 25%
Moderately successful • 25%
Delayed • 25%
Cancelled • 25%
Operational • 25%
Testing phase • 25%
Yes • 50%
No • 50%
No • 50%
Yes • 50%
Successful completion but no expansion • 25%
Ongoing trials with no decision • 25%
Successful completion and expansion approved • 25%
Trials discontinued • 25%